A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ruihua Xu, Doctor
- Phone Number: 020-87343468
- Email: xurh@syscc.org.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Not yet recruiting
- Peking University First Hospital
-
Contact:
- Shikai Wu, Doctor
- Phone Number: 15810037307
- Email: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400016
- Not yet recruiting
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Tao Zhang, Doctor
- Phone Number: 13708311156
- Email: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730050
- Not yet recruiting
- Gansu Provincial Tumor Hospital
-
Contact:
- Zhihu Li, Master
- Phone Number: 18993042850
- Email: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, China, 528000
- Not yet recruiting
- The First People's Hospital of Foshan
-
Contact:
- Wei Wang, Doctor
- Phone Number: 18038863618
- Email: wangwei@fsyyy.com
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Ruihua Xu, Doctor
- Phone Number: 020-87343468
- Email: xurh@syscc.org.cn
-
Guangzhou, Guangdong, China, 510000
- Not yet recruiting
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Yanhon Den, Doctor
- Phone Number: 13925106525
- Email: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, China, 530000
- Not yet recruiting
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Contact:
- Rong Liang, Doctor
- Phone Number: 18677070811
- Email: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, China, 563000
- Recruiting
- The Affiliated Hospital of Zunyi Medical University
-
Contact:
- Jiwei Wang, Doctor
- Phone Number: 18013964231
- Email: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Not yet recruiting
- Harbin Medical University Cancer Hospital
-
Contact:
- Tongsen Zheng, Doctor
- Phone Number: 15134569619
- Email: zhengtongsen@126.com
-
Contact:
- Yuxian Bai, Doctor
- Phone Number: 13945095085
- Email: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, China, 161005
- Not yet recruiting
- Qiqihar First Hospital
-
Contact:
- Xiyuan Sun, Doctor
- Phone Number: 13945258792
- Email: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Not yet recruiting
- Henan Cancer Hospital
-
Contact:
- Ying Liu, Doctor
- Phone Number: 13783604602
- Email: yaya7207@126.com
-
Zhengzhou, Henan, China, 450000
- Not yet recruiting
- The Third People's Hospital of Zhengzhou
-
Contact:
- HaiCun Wang, Master
- Phone Number: 13803833783
- Email: whc1975@126.com
-
Zhengzhou, Henan, China, 450000
- Not yet recruiting
- The first affiliated hospital of Zhengzhou university
-
Contact:
- Yongxu Jia, Doctor
- Phone Number: 15237128281
- Email: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, China, 434099
- Not yet recruiting
- Jingzhou First People's Hospital
-
Contact:
- Yan Hu, Master
- Phone Number: 18163137369
- Email: helensparkle@163.com
-
Wuhan, Hubei, China, 430022
- Not yet recruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Hongli Liu, Doctor
- Phone Number: 13995680822
- Email: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Yi He, Doctor
- Phone Number: 18692237222
- Email: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital
-
Contact:
- Yudong Qiu, Doctor
- Phone Number: 13951806490
- Email: yudongqiu510@163.com
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Zhongda Hospital Southeast University
-
Contact:
- CaiLian Wang, Doctor
- Phone Number: 13851756378
- Email: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, China, 210000
- Not yet recruiting
- Jiangsu Provincial Cancer Hospital
-
Contact:
- Yuanhua Liu, Doctor
- Phone Number: 13305180356
- Email: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Not yet recruiting
- Jiangxi Provincal People's Hospital
-
Contact:
- Weirong Yao, Doctor
- Phone Number: 13907002901
- Email: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Not yet recruiting
- Jilin Cancer Hospital
-
Contact:
- Hongxia Cui, Master
- Phone Number: 13504436090
- Email: 2503074283@qq.com
-
Changchun, Jilin, China, 130021
- Not yet recruiting
- The first hospital of Jilin University
-
Contact:
- Tingting Liang, Doctor
- Phone Number: 15804303776
- Email: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Recruiting
- Liaoning Cancer Hospital & Institute
-
Contact:
- Jingdong Zhang, Doctor
- Phone Number: 18040007878
- Email: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Not yet recruiting
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Contact:
- Aili Suo, Doctor
- Phone Number: 18991232561
- Email: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200127
- Recruiting
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- XiuYing Xiao, Doctor
- Phone Number: 13564579313
- Email: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, China, 710000
- Not yet recruiting
- The Second Affiliated Hospital of Air Force Medical University
-
Contact:
- Haichuan Su, Doctor
- Phone Number: 18629190366
- Email: cntdgcp@163.com
-
Xi’an, Shanxi, China, 710000
- Not yet recruiting
- The First Affiliated Hospital of Air Force Medical University
-
Contact:
- Yongzhan Nie, Doctor
- Phone Number: 15091520001
- Email: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300202
- Recruiting
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Zhanyu Pan, Master
- Phone Number: 18622221256
- Email: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, China, 300121
- Not yet recruiting
- Tianjin Union Medical Center
-
Contact:
- Mingqing Zhang, Doctor
- Phone Number: 15122875158
- Email: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830054
- Not yet recruiting
- Xinjiang Medical University Affiliated Tumor Hospital
-
Contact:
- YanLi Qu, Master
- Phone Number: 18160627963
- Email: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, China, 323000
- Recruiting
- Lishui Municipal Central Hospital
-
Contact:
- Yanru Xie, Master
- Phone Number: 13567615770
- Email: 43437677@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Active Comparator: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recommended Phase 2 Dose
Time Frame: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Time Frame: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Time Frame: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Half-life
Time Frame: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Time Frame: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Time Frame: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Time Frame: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Time Frame: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Time Frame: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Time Frame: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Time Frame: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Time Frame: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Time Frame: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TQB2930-Ib/II-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.